查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466630

抗体药物复合体市场：按作用机制、药物、技术、适应症和最终用户 - 2024-2030 年全球预测

Antibody Drug Conjugate Market by Mechanism of Action (CD30 Antibodies, ErbB2 Antibodies), Drugs (Adcetris, Blenrep, Enhertu), Technology, Indication, End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年抗体药物复合体市场规模为56亿美元，预计2024年将达到64.8亿美元，2030年将达到159.6亿美元，复合年增长率为16.12%。

抗体药物复合体(ADC) 涉及结合单株抗体和细胞毒性药物的治疗分子的开发、製造和商业化。这些混合化合物选择性地靶向并消除癌细胞，同时最大限度地减少对健康组织的毒性。与传统化疗相比，ADC 因其疗效提高和副作用减少而广泛应用于肿瘤学。全球癌症发生率的持续上升增加了对 ADC 等创新治疗方法的需求。然而，ADC 的製造过程可能复杂且具有挑战性，需要多个步骤和严格的品管措施来确保产品的同质性和稳定性。针对 ADC 技术在癌症以外的疾病（例如自体免疫疾病和感染疾病）的应用的研究也在进行中，预计将加速全球最终用途部门对 ADC 的使用。

主要市场统计
基准年[2023] 56亿美元
预测年份 [2024] 64.8亿美元
预测年份 [2030] 159.6亿美元
复合年增长率（%） 16.12%

作用机转：ErbB2 抗体 (HER2) 作为乳癌和胃癌的有效治疗方法越来越受到青睐

CD30 抗体是一种针对 CD30 抗原的 ADC（抗体药物复合体），该抗原在多种类型的癌症中过度表达，包括异生性大细胞淋巴瘤、何杰金氏淋巴瘤和其他 T 细胞淋巴瘤。这些 ADC 在临床试验中显示出有希望的结果，并因其在向癌细胞输送细胞毒性药物同时保护健康组织方面的效率和特异性而被广泛使用。 ErbB2 抗体是另一类针对人类表皮生长因子受体 2 (HER2) 的 ADC，HER2 在癌细胞增殖中扮演重要角色。 HER2 过度表现发生在多种恶性中，包括乳癌和胃癌。 ErbB2 标靶 ADC 可有效改善这些常规治疗方法失败的疾病患者的预后。

药物：Enhertz 作为癌症领域标靶治疗的有前景药物的渗透

ADCETRIS（brentuximab vedotin）用于治疗多种淋巴瘤亚型，包括异生性大细胞淋巴瘤（ALCL）、何杰金氏淋巴瘤（HL）和周边T细胞淋巴瘤（PTCL）。其临床成功归因于其能够使用一种名为单甲基auristatin E (MMAE)的强效细胞毒性药物靶向表达CD30的癌细胞，该药物此前限制了治疗选择，从而提高了患者的整体生存率。 Brenrep（belantamab mafodotin blmf）解决了治疗復发性或难治性多发性骨髓瘤中未满足的需求。它透过施用一种名为单甲基auristatin F (MMAF) 的强效微管破坏剂来靶向恶性浆细胞上的 B 细胞成熟抗原 (BCMA)。 Enhertu（fam-trastuzumab deruxtecan-nxki）是为治疗转移性 HER2 阳性乳癌而开发的，与曲妥珠单抗 emtansine (T-DM1) 等标准治疗相比，无恶化无恶化生存期显着增加。 Kadcyla（Ado-trastuzumab Emtansine）是一种治疗 HER2 阳性转移性乳癌患者的药物。它用于先前接受过曲妥珠单抗和紫杉烷治疗的患者。其独特的作用机制是将一种称为 DM1 的高效细胞毒性药物标靶递送至 HER2 过度表现的癌细胞。 Padoseb（enfortumab vedotin-ejfv）用于治疗晚期尿路上皮癌，具有很高的未满足的医疗需求。它选择性地靶向在尿路上皮癌中高表达的黏附分子Nectin-4，并直接向癌细胞施用强效细胞毒剂MMAE。 Trodelvy (sacituzumab govitecan-hziy) 解决了三阴性乳癌 (TNBC) 治疗中未满足的需求，其特点是治疗选择有限且预后不良。

技术：优先考虑无连结器技术，以简化製造流程并提高 ADC 稳定性

可裂解接头技术旨在透过特定的酶促或化学裂解在癌细胞内选择性释放细胞毒性药物。这种方法提高了治疗效果，同时最大限度地减少了脱靶毒性。无连接 ADC 将细胞毒性药物直接附着到抗体上，无需使用额外的连接分子。这简化了製造流程并提高了ADC产品的稳定性和同质性。不可溶性接头坚固且稳定，旨在在被目标癌细胞摄取后释放细胞毒性有效负载，同时在血流中保持完整。不可降解连接体的优点是稳定性高，可降低药物过早释放和脱靶毒性的风险。可切割接头在癌细胞内选择性活化并抑制脱靶毒性，但与其他技术相比可能会遭受系统性不稳定的影响。无连结 ADC 可以简化製造流程并提高产品同质性，但可能用途较差，因为它们需要直接缀合。儘管不可可溶性连接体提高了血流内的稳定性，但有效的药物释放高度依赖抗体的有效内化。

适应症：快速使用ADC有效治疗乳癌

ADC 是治疗淋巴瘤、白血病和多发性骨髓瘤等血癌的可靠治疗方法，因为它们可以针对恶性细胞上表现的肿瘤特异性抗原，同时不伤害正常造血细胞。 ADC 由于能够针对过度表达的受体（包括 HER2），因此在乳癌治疗中受到关注。 ADC 广泛用于治疗白血病，这是一种以快速产生异常白血球为特征的血癌。淋巴瘤是淋巴系统的癌症，分为何何杰金氏病型和非何何杰金氏病型。针对恶性淋巴细胞上特异性抗原的 ADC 已有效治疗这些癌症。多发性骨髓瘤是一种影响骨髓的浆细胞癌，靶向 B 细胞成熟抗原 (BCMA) 的 ADC 在治疗这种恶性方面已显示出前景。 ADC 也显示出治疗尿路上皮癌和膀胱癌的潜力，因为它们能够针对这些恶性中过度表现的特定蛋白质。

最终用户：学术研究机构新开发的ADC新用途

在学术研究机构中，ADC 对于提高我们对癌症生物学和治疗机制的理解至关重要。研究人员正在使用 ADC 来研究癌细胞与肿瘤微环境之间的复杂相互作用。生物製药和生物技术公司处于 ADC 开发和商业化的前沿，大力投资研发工作，以发现新的抗体药物复合体物标靶和有效负载，同时改进药物连接器技术。医院在透​​过临床试验检验ADC 的有效性方面也发挥着至关重要的作用。癌症中心是跨学科专业知识和最尖端科技的中心，促进研究成果转化为临床实践。癌症中心创造了一个肿瘤学家、病理学家、药理学家和放射学家合作的环境，透过精准医疗改善病患照护。

区域洞察

由于肿瘤学的进步和对标靶治疗的需求，抗体药物复合体（ADC）市场正在美洲发展。强大的研究基础设施和有利的创新环境正在推动 ADC 在美洲的发展。在欧盟 (EU)，ADC 的中央行销核准由欧洲药品管理局 (EMA) 进行。近年来，欧盟开展了多项开发新型 ADC 疗法的策略合作。由于医疗支出的增加和标靶治疗意识的增强，中东和非洲地区的潜力开拓。不断上升的研发成本和癌症的流行正在推动亚太地区对 ADC 的需求。此外，在 ADC 製造中引入和利用先进技术预计将增加其在全球最终用途领域的采用。

FPNV定位矩阵

FPNV定位矩阵对于评估抗体药物复合体市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对抗体药物复合体市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.抗体药物复合体市场规模及预测如何？

2.抗体药物复合体市场预测期间需要考虑投资的产品、细分市场、应用和领域有哪些？

3.抗体药物复合体市场的技术趋势和法规结构是什么？

4.抗体药物复合体市场主要供应商的市场占有率是多少？

5. 进入抗体药物复合体市场的合适形式和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球癌症发生率增加
      • 临床试验活动的成长和强大的产品平臺
      • 政府对癌症研究的支持与努力
    • 抑制因素
      • 高 ADC 製造成本和产品召回
    • 机会
      • 加大生物製药研发投入并推出新型ADC
      • 采用先进技术进行ADC开发
    • 任务
      • ADC 製造复杂性
  • 市场区隔分析
    • 作用机转：提高ErbB2抗体（HER2）有效治疗乳癌和胃癌的优越性
    • 药物：Enhertz 作为一种有前景的肿瘤标靶治疗药物的渗透
    • 技术：优先采用无连结器技术来简化製造流程并提高 ADC 稳定性
    • 适应症：快速使用ADC有效治疗乳癌
    • 最终用户：学术研究机构新开发的ADC新用途
  • 市场趋势分析
    • 专注于确保新 ADC 药物在美洲获得核准
    • 改善亚太地区癌症和医疗基础设施的负担
    • 政府支持活动以改善欧洲、中东和非洲的癌症研究和治疗
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析

第六章抗体药物复合体市场：按作用机制

  • CD30抗体
  • ErbB2抗体

第七章抗体药物复合体市场：依药物分类

  • ADCETRIS
  • 布伦代表
  • 恩赫图
  • 门头
  • 帕多切夫
  • 特罗德维

第八章抗体药物复合体市场：依技术分类

  • 可切割接头
  • 无连结器
  • 不可切割的接头

第九章抗体药物复合体市场：依适应症分类

  • 血癌
  • 乳癌
  • 淋巴瘤
  • 多发性骨髓瘤
  • 尿路上皮癌和膀胱癌

第10章抗体药物复合体市场：依最终用户分类

  • 学术研究所
  • 生物製药和生物技术公司
  • 医院
  • 专门癌症中心

第十一章美洲抗体药物复合体市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太抗体抗体药物复合体市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲抗体药物复合体市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 市场占有率分析（2023）
  • FPNV定位矩阵（2023）
  • 竞争情境分析
    • Lonza 加强抗体药物复合体的商业供给能力
    • CHMP 建议欧盟核准ENHERTU 用于治疗 HER2 突变的晚期非小细胞肺癌患者
    • Pyxis Oncology 完成对 Apexigen 的收购
    • 百济神与 DualityBio 宣布合作推进固态肿瘤差异化抗体药物复合体(ADC) 疗法
    • 诺华支持的 Tagworks 筹集了 6,500 万美元的 A 轮融资，以进一步推进 ADC、点击发布技术
    • Lonza 收购 Synafix 以加强抗体药物复合体产品
    • 索尼和安斯泰来签署合作研究协议，探索新的肿瘤学 ADC 平台
    • BioNTech 与 DualityBio 建立全球战略合作伙伴关係，加速固态肿瘤差异化抗体药物复合体疗法的开发
    • 辉瑞投资430亿美元对抗癌症
    • 阿斯特捷利康与 KYM Biosciences 签署 Claudin-18.2抗体药物复合体CMG901授权合约
    • 美国FDA核准Trodelvy 用于治疗先前接受过治疗的 HR+/HER2- 转移性乳癌患者

第15章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-657F2A76F4DB

[195 Pages Report] The Antibody Drug Conjugate Market size was estimated at USD 5.60 billion in 2023 and expected to reach USD 6.48 billion in 2024, at a CAGR 16.12% to reach USD 15.96 billion by 2030.

The antibody drug conjugate (ADC) includes developing, manufacturing, and commercializing therapeutic molecules that combine monoclonal antibodies with cytotoxic agents. These hybrid compounds selectively target and eliminate cancer cells while minimizing toxicity to healthy tissue. ADCs are widely used in oncology due to their enhanced efficacy and reduced side effects compared to traditional chemotherapy. The continuous rise in cancer prevalence globally fuels the need for innovative therapies such as ADCs. However, the complexity of the manufacturing process for ADCs can be challenging, as they require multiple steps and stringent quality control measures to ensure product homogeneity and stability. Moreover, research is being conducted on applying ADC technologies to other diseases beyond oncology, including autoimmune disorders and infectious diseases, which is expected to encourage the utilization of ADCs by the end-use sectors worldwide.

KEY MARKET STATISTICS
Base Year [2023] USD 5.60 billion
Estimated Year [2024] USD 6.48 billion
Forecast Year [2030] USD 15.96 billion
CAGR (%) 16.12%

Mechanism of Action: Increasing preference for ErbB2 antibodies (HER2) for effective treatment of breast and gastric cancer

CD30 antibodies are a class of antibody drug conjugates (ADCs) that target the CD30 antigen, which is overexpressed in several types of cancers such as anaplastic large cell lymphoma, Hodgkin's lymphoma, and other T-cell lymphomas. These ADCs have exhibited promising results in clinical trials and have been widely used for their efficiency and specificity in delivering cytotoxic agents to cancer cells while sparing healthy tissues. ErbB2 antibodies are another class of ADCs that target the human epidermal growth factor receptor 2 (HER2), which plays a crucial role in the proliferation of cancer cells. Overexpression of HER2 occurs in various malignancies, including breast cancer and gastric cancer. ErbB2-targeting ADCs have been effective in improving outcomes for patients suffering from these diseases where traditional therapies have failed.

Drugs: Penetration of Enhertu as a promising drug for targeted therapies in the oncology field

Adcetris (brentuximab vedotin) is employed for the treatment of various lymphoma subtypes, such as anaplastic large cell lymphoma (ALCL), Hodgkin's lymphoma (HL), and peripheral T-cell lymphomas (PTCL). Its clinical success is attributed to its ability to target CD30-expressing cancer cells with a potent cytotoxic agent known as monomethyl auristatin E (MMAE), leading to enhanced overall survival rates in patients with limited treatment options in the past. Blenrep (belantamab mafodotin-blmf) addresses an unmet need in treating relapsed or refractory multiple myeloma. It targets B-cell maturation antigen (BCMA) on malignant plasma cells by delivering a potent microtubule-disrupting agent called monomethyl auristatin F (MMAF). Enhertu (fam-trastuzumab deruxtecan-nxki) was developed for the treatment of metastatic HER2-positive breast cancer and has demonstrated significant advancement in progression-free survival as compared to standard therapies such as trastuzumab emtansine (T-DM1). Kadcyla (ado-trastuzumab emtansine) is a solution for patients with HER2-positive metastatic breast cancer. It is used in patients previously treated with trastuzumab and taxane therapy. Its unique mechanism of action involves the targeted delivery of a highly potent cytotoxic agent called DM1 to HER2-overexpressing tumor cells. Padcev (enfortumab vedotin-ejfv) is used to treat advanced urothelial cancer, representing a considerable unmet medical need. It selectively targets Nectin-4, an adhesion molecule highly expressed in urothelial cancers, and delivers the potent cytotoxic agent MMAE directly to tumor cells. Trodelvy (sacituzumab govitecan-hziy) addresses an unmet need in treating triple-negative breast cancer (TNBC), a subtype characterized by limited therapeutic options and poor prognosis.

Technology: Preference for linkerless technology for simplifying the manufacturing process and improving the stability of ADCs

The cleavable linker technology is designed to release the cytotoxic drug selectively within the tumor cells through specific enzymatic or chemical cleavage. This approach increases therapeutic efficacy while minimizing off-target toxicities. Linkerless ADCs employ direct conjugation of the cytotoxic drug to the antibody without using any additional linker molecules. This simplifies the manufacturing process and improves the stability and homogeneity of ADC products. Non-cleavable linkers are robust and stable, designed to remain intact within the bloodstream while releasing their cytotoxic payload upon internalization into targeted tumor cells. The advantage of non-cleavable linkers is their enhanced stability, reducing the risk of premature drug release and off-target toxicity. Cleavable linkers provide selective activation within tumor cells, limiting off-target toxicities; however, they may suffer from higher systemic instability than other technologies. Linkerless ADCs offer streamlined manufacturing processes and possible improvements in product homogeneity and may be less versatile due to direct conjugation requirements. Non-cleavable linkers offer increased stability within the bloodstream; however, they rely heavily on efficient antibody internalization for effective drug release.

Indication: Rapid usage of ADCs for efficient treatment of breast cancer

ADCs have emerged as a reliable therapy for blood cancers, including lymphoma, leukemia, and multiple myeloma, due to their ability to target tumor-specific antigens expressed on malignant cells while sparing normal hematopoietic cells. ADCs are gaining attention in breast cancer treatment due to their ability to target overexpressed receptors, including HER2. ADCs are widely used in treating leukemia, a blood cancer characterized by the rapid production of abnormal white blood cells. Lymphomas are cancers of the lymphatic system and include Hodgkin and non-Hodgkin subtypes. ADCs targeting specific antigens on malignant lymphocytes have effectively treated these cancers. Multiple myeloma is a type of cancer of plasma cells that affects bone marrow, and ADCs targeting B-cell maturation antigen (BCMA) show potential for treating this malignancy. ADCs also demonstrate potential in urothelial and bladder cancer treatment owing to their ability to target specific proteins overexpressed in these malignancies.

End User: Emerging use of ADCs by academic research institutes for novel developments

In academic research institutes, ADCs are essential in extending the understanding of cancer biology and therapeutic mechanisms. Researchers use ADCs to explore the complex interactions between tumor cells and the tumor microenvironment. Biopharmaceutical and biotechnology companies are at the forefront of ADC development and commercialization by investing heavily in R&D activities for discovering new antibody drug conjugate targets and payloads while improving drug-linker technologies. Hospitals also play a pivotal role in validating the effectiveness of ADCs through clinical trials. Specialized cancer centers serve as hubs for multidisciplinary expertise and state-of-the-art technologies that facilitate the translation of research findings into clinical practice. Specialized cancer centers foster an environment of collaboration between oncologists, pathologists, pharmacologists, and radiologists to enhance patient care through precision medicine.

Regional Insights

The antibody drug conjugates (ADCs) market is evolving in the Americas due to advancements in oncology and the need for targeted therapies. A robust research infrastructure and a favorable environment for innovation encourage growth of ADCs in the Americas. In the European Union (EU), centralized marketing authorization for ADCs is provided by the European Medicines Agency (EMA). The EU has observed several strategic collaborations to develop novel ADC therapy in recent years. The Middle East and Africa region presents untapped potential due to increasing healthcare expenditure and growing awareness of targeted therapies. Increasing R&D expenditure coupled with the prevalence of cancer are raising the need for ADCs in the APAC region. Additionally, introducing and utilizing advanced technologies for manufacturing ADCs is anticipated to increase their adoption by the end-use sectors across the globe.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antibody Drug Conjugate Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibody Drug Conjugate Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antibody Drug Conjugate Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., ADC Therapeutics SA, Ambrx Biopharma Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BioNTech SE, Bristol-Myers Squibb Company, Byondis B.V., Celldex Therapeutics Inc., Creative Biolabs, Inc., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Heidelberg Pharma AG, ImmunoGen, Inc., Innate Pharma SA, Innovent Biologics, Inc., Lonza Group Ltd., MacroGenics, Inc., MediLink Therapeutics, Merck KGaA, Mersana Therapeutics, Inc., Novartis AG, Oxford Biotherapeutics Limited, Pfizer, Inc., Pheon Therapeutics Ltd., Piramal Pharma Limited, Recipharm AB, Sanofi S.A., Sorrento Therapeutics, Inc., Tagworks Pharmaceuticals BV, Takeda Pharmaceutical Company Limited, Tubulis GmbH, and Zymeworks Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Drug Conjugate Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Mechanism of Action
    • CD30 Antibodies
    • ErbB2 Antibodies
  • Drugs
    • Adcetris
    • Blenrep
    • Enhertu
    • Kadcyla
    • Padcev
    • Trodelvy
  • Technology
    • Cleavable Linker
    • Linkerless
    • Non-Cleavable Linker
  • Indication
    • Blood Cancer
    • Breast Cancer
    • Lymphoma
    • Multiple Myeloma
    • Urothelial Cancer & Bladder Cancer
  • End User
    • Academic Research Institutes
    • Biopharmaceutical & Biotechnology Companies
    • Hospitals
    • Specialized Cancer Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • Alaska
        • California
        • Florida
        • Illinois
        • Massachusetts
        • Michigan
        • Montana
        • Nevada
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antibody Drug Conjugate Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibody Drug Conjugate Market?

3. What are the technology trends and regulatory frameworks in the Antibody Drug Conjugate Market?

4. What is the market share of the leading vendors in the Antibody Drug Conjugate Market?

5. Which modes and strategic moves are suitable for entering the Antibody Drug Conjugate Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer worldwide
      • 5.1.1.2. Growth in clinical trial activities and robust product pipeline
      • 5.1.1.3. Government support and initiatives encouraging research on cancer
    • 5.1.2. Restraints
      • 5.1.2.1. High manufacturing cost of ADC and incidences of product recalls
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investment in biopharma R&D and introduction of novel ADCs
      • 5.1.3.2. Adoption of advanced technologies for developing ADC
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in manufacturing of ADCs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Mechanism of Action: Increasing preference for ErbB2 antibodies (HER2) for effective treatment of breast and gastric cancer
    • 5.2.2. Drugs: Penetration of Enhertu as a promising drug for targeted therapies in the oncology field
    • 5.2.3. Technology: Preference for linkerless technology for simplifying the manufacturing process and improving the stability of ADCs
    • 5.2.4. Indication: Rapid usage of ADCs for efficient treatment of breast cancer
    • 5.2.5. End User: Emerging use of ADCs by academic research institutes for novel developments
  • 5.3. Market Trend Analysis
    • 5.3.1. Significant emphasis on securing approval for novel ADC drugs in the Americas
    • 5.3.2. Cancer burden coupled with improving healthcare infrastructure in the APAC region
    • 5.3.3. Supportive government initiatives for improved cancer research and treatment in the EMEA region
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Antibody Drug Conjugate Market, by Mechanism of Action

  • 6.1. Introduction
  • 6.2. CD30 Antibodies
  • 6.3. ErbB2 Antibodies

7. Antibody Drug Conjugate Market, by Drugs

  • 7.1. Introduction
  • 7.2. Adcetris
  • 7.3. Blenrep
  • 7.4. Enhertu
  • 7.5. Kadcyla
  • 7.6. Padcev
  • 7.7. Trodelvy

8. Antibody Drug Conjugate Market, by Technology

  • 8.1. Introduction
  • 8.2. Cleavable Linker
  • 8.3. Linkerless
  • 8.4. Non-Cleavable Linker

9. Antibody Drug Conjugate Market, by Indication

  • 9.1. Introduction
  • 9.2. Blood Cancer
  • 9.3. Breast Cancer
  • 9.4. Lymphoma
  • 9.5. Multiple Myeloma
  • 9.6. Urothelial Cancer & Bladder Cancer

10. Antibody Drug Conjugate Market, by End User

  • 10.1. Introduction
  • 10.2. Academic Research Institutes
  • 10.3. Biopharmaceutical & Biotechnology Companies
  • 10.4. Hospitals
  • 10.5. Specialized Cancer Centers

11. Americas Antibody Drug Conjugate Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Antibody Drug Conjugate Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Antibody Drug Conjugate Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Lonza to enhance commercial antibody-drug conjugate supply capacity
    • 14.3.2. ENHERTU Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer
    • 14.3.3. Pyxis Oncology Successfully Completes Acquisition of Apexigen
    • 14.3.4. BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
    • 14.3.5. Novartis-Backed Tagworks Raises USD 65 Million Series A to Further ADC, Click-to-Release Tech
    • 14.3.6. Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
    • 14.3.7. Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field
    • 14.3.8. BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
    • 14.3.9. Pfizer Invests USD 43 Billion to Battle Cancer
    • 14.3.10. AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate
    • 14.3.11. U.S. FDA Approves Trodelvy in Pre-treated HR+/HER2- Metastatic Breast Cancer

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. ANTIBODY DRUG CONJUGATE MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODY DRUG CONJUGATE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTIBODY DRUG CONJUGATE MARKET DYNAMICS
  • FIGURE 7. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. ANTIBODY DRUG CONJUGATE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. ANTIBODY DRUG CONJUGATE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIBODY DRUG CONJUGATE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CD30 ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CD30 ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ERBB2 ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ERBB2 ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ADCETRIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ADCETRIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLENREP, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLENREP, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ENHERTU, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ENHERTU, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY KADCYLA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY KADCYLA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PADCEV, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PADCEV, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TRODELVY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TRODELVY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE LINKER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE LINKER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKERLESS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKERLESS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON-CLEAVABLE LINKER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON-CLEAVABLE LINKER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLOOD CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LYMPHOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY UROTHELIAL CANCER & BLADDER CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY UROTHELIAL CANCER & BLADDER CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SPECIALIZED CANCER CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SPECIALIZED CANCER CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 77. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 78. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 97. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 98. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 107. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 108. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 119. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 120. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 136. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 138. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 140. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 142. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 145. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 146. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 147. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 148. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 149. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 150. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 151. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 152. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 155. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 156. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 157. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 158. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 159. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 160. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 161. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 162. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 163. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 164. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 165. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 166. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 167. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 168. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 169. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 170. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 171. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 172. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 173. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 174. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 175. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 176. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 177. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 178. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 179. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 180. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 181. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 182. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 183. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 184. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 185. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 186. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 187. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 188. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 189. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 190. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 191. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 192. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 194. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 196. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 198. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 200. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 202. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 203. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 204. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 205. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 206. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 207. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 208. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 209. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 210. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 211. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 212. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 214. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 216. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 218. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 220. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 222. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 223. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 224. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 225. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 226. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 227. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 228. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 229. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 230. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 231. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 232. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 233. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 234. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 235. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 236. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 237. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 238. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 239. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 240. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 241. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 242. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 243. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 244. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 245. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 246. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 247. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 248. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 249. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 250. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 251. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 252. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 265. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 266. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 267. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 268. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 269. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 270. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 271. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 272. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 273. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 274. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 275. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 276. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 277. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 278. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 279. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 280. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 281. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 282. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 283. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 284. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 285. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 286. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 287. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 288. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 289. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 290. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 291. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 292. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 293. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 294. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 295. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 296. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 297. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 298. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 299. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 300. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 301. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 302. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 303. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 304. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 305. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 306. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 307. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 308. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 309. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 310. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 311. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 312. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 313. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 314. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 315. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 316. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 317. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 318. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 319. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 320. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 321. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 322. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 323. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 324. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 325. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 326. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 327. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 328. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 329. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 330. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 331. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 332. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 333. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 334. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 335. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 336. NETHERLANDS ANTIBODY DRUG